Current pharmaceutical biotechnologyJul 23, 2026

Using Positively Charged Lipid Nanoparticles to Deliver miR-34A to Lung Cancer Cells: Comparing DNA and RNA Formulations

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 24, 2026

Abstract

A cationic lipid nanoparticle (cLNP) system was developed for the delivery of miRNAs to cancer cells.

MicroRNAs (miRNAs) may serve as effective diagnostic biomarkers and therapeutic agents.
The tumor-suppressor miR-34a is downregulated in various cancers.
Efficient and safe delivery systems for miR-34a are currently lacking in clinical applications.

Simplified

MicroRNAs (miRNAs) are promising diagnostic biomarkers and therapeutic agents with therapeutic applications based on either miRNA mimics or antagonists. The objective of this study was to develop a cationic lipid nanoparticle (cLNP) system for the targeted delivery of miRNAs to cancer cells. We focused on the tumor-suppressor miR-34a, which is downregulated in many cancers, yet its clinical use remains limited by the lack of an efficient and safe delivery system.

Full Text

Full text is available at the source.

View Full Text ↗

Using Positively Charged Lipid Nanoparticles to Deliver miR-34A to Lung Cancer Cells: Comparing DNA and RNA Formulations

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief